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Abstract
Glycosylation is highly sensitive to the biochemical environment and has been implicated in many
diseases including cancer. Glycan compositional profiling of human serum with mass
spectrometry has already identified potential biomarkers for several types of cancer and diseases;
however, composition alone does not fully describe glycan stereo- and regioisomeric diversity.
The vast structural heterogeneity of glycans presents a formidable analytical challenge. We have
developed a method to identify and quantify isomeric native glycans using nanoflow liquid
chromatography (nano-LC)/mass spectrometry. A microfluidic chip packed with graphitized
carbon was used to chromatographically separate the glycans. To determine the utility of this
method for structure-specific biomarker discovery, we analyzed serum samples from two groups
of prostate cancer patients with different prognoses. More than 300 N-glycan species (including
isomeric structures) were identified, corresponding to over 100 N-glycan compositions. Statistical
tests established significant differences in glycan abundances between patient groups. This method
provides comprehensive, selective, and quantitative glycan profiling.
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INTRODUCTION
Aberrant glycosylation has been observed for decades in nearly all types of human cancer
and is now quite well established as an indicator of cell oncogenic transformation.1, 2
Glycans are important determinants of protein function, and many cancer-related processes
such as apoptosis,3, 4 angiogenesis,5, 6 growth factor receptor binding,7-9 or integrin-
cadherin function10, 11 are profoundly affected by changes in glycosylation. The
glycosylation machinery involves competition between a set of glycosyltransferase enzymes
such that up- or down-regulation of an individual transferase is amplified across the entire
glycan biosynthetic pathway.2 Examples of aberrant glycosylation associated with disease
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states are rampant in the literature and include variations in the amount of specific
saccharide residues, expression of incomplete or truncated glycan structures, and increases
or decreases in the relative abundance of certain glycan species.1, 12, 13
Glycans, consisting of short saccharide chains of two to twenty units, are the only post-
translational modification with significant structural complexity. Whereas sequence is
sufficient to determine the primary structures of linear biomolecules such as nucleic acids
and proteins, glycans are branched, with linkage and anomeric characters. For example, a
standard hexose has five different sites at which it may be connected to other saccharide
units. When anomeric character is considered, the possibilities increase to ten unique
potential linkages. In addition, branching is theoretically possible at every residue. The
plethora of stereo- and regio-isomeric possibilities greatly increases the complexity of
oligosaccharide analysis.
Until now, the search for glycan biomarkers has focused mainly on glycan compositional
profiling.14-20 However, structure-specific glycan profiling may uncover more robust glycan
markers with higher specificity than compositional profiling alone. Changes in specific
saccharide linkages have been associated with diseases such as pancreatic cancer and
Alzheimer’s disease.21, 22 Since the number of glycan structures greatly surpasses the
number of compositions, structure-specific profiling provides more biological information
and thus serves as a significantly larger source of potential glycan biomarkers.23, 24 In order
to gain structure-specific access to individual glycan species, isomer separation is required.
Glycan chromatographic profiling enables not only the discovery of structure-specific
markers but also unprecedented structural analysis of the glycome. This method
complements our previously-developed strategies of glycan mass profiling by high
resolution mass spectrometry, which provides rapid compositional analysis based on
accurate mass.14-17 Each mass or composition identified by non-chromatographic MS
analysis is made up of several distinct structures. Chromatographic profiling, coupled with
mass spectrometry, allows these structures to be separated and specific sugar-sugar linkage
types examined.
Limited attempts at glycan isomeric differentiation and characterization have been reported.
Isailovic et al used ion mobility mass spectrometry to interrogate derivatized serum glycans
from cancer patients.25 Peak perturbations in the ion mobility spectrum were attributed to
partial separation of glycan isomers or conformers. Nakagawa et al employed a more
traditional reversed phase LC/MS-based approach to analyze N-glycan isomers from
rheumatoid arthritis patients; however, glycans had to be desialylated and then derivatized
prior to analysis.26 Bones et al attempted a non-MS approach involving ultra performance
LC and fluorescence detection of labeled N-glycans.27 In contrast, Prien et al employed a
wholly non-chromatographic approach using MSn to differentiate structural isomers for a
small number of derivatized glycans isolated from tumor cells.28 Studies on isomeric
separation of native glycans are essentially non-existent in the literature. However, for
biomarker-related applications, minimal sample manipulation and processing are preferred,
so as to preserve the original glycan profile and maximize method reproducibility. Thus, for
this study, native, underivatized glycans were analyzed.
Our group was first to use microfluidic chip-based nano-LC for the global separation of
serum glycans.29 Nano-LC/MS provides significantly greater sensitivity compared to
conventional LC/MS or MALDI-MS.18, 19 In addition, nano-LC-ESI/MS generally produces
low energy ions and therefore yields less in-source fragmentation than MALDI. The
microfluidic chip is the latest evolution of nano-LC, providing unmatched retention time
reproducibility.30 Coupling chip-based nano-LC technology with nano-ESI and a high
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performance time-of-flight (TOF) MS detector provides the added benefits of high mass
accuracy and a wide instrumental dynamic range.31-34
In this study we developed and optimized a method to chromatographically separate and
profile native serum N-glycans by porous graphitized carbon (PGC) nano-LC/TOF-MS for
the purposes of identifying structure-specific glycan biomarkers. Using this method, serum
N-glycan samples from prostate cancer patients were profiled both by overall compositional
abundance and in relation to specific isomers. Patients with poor prognoses (P group) and
good prognoses (G group) were compared according to individual glycan abundances.
Statistical tests were performed to establish significant differences. Isomer-specific glycan
chromatographic profiling will supplement and augment glycan compositional profiling
achieved by MS analysis by identifying the specific glycan structures that vary according to
disease.
EXPERIMENTAL
Collection of human sera
Serum samples were collected from patients who had been diagnosed with prostate cancer
and were seen at the UC Davis Cancer Center. Their samples were procured by the Cancer
Center Biorepository via an IRB-approved protocol. Patients were divided into two groups
based on PSA (prostate-specific antigen) levels. The P group (n = 4) consisted of patients
with poor prognoses based on elevated PSA levels post-RRP (radical retropubic
prostatectomy), while the G group (n = 4) consisted of patients with good prognoses based
on undetectable PSA levels post-RRP. Serum samples were collected by standard venous
phlebotomy into a clot-activator vacuum blood collection tube (BD Diagnostics, Franklin
Lakes, NJ).
Enzymatic release of N-glycans
Denaturation buffer consisting of 200 mM ammonium bicarbonate and 10 mM dithiothreitol
was prepared. A 100 μL aliquot of serum was added to 100 μL of denaturation buffer and
heated to 100 °C in order to denature the serum proteins. After cooling, 2.0 μL of peptide N-
glycosidase F (New England Biolabs, Ipswich, MA) were added and the mixture was
incubated in a water bath at 37 °C for 12 hours in order to enzymatically release the N-
glycans. Finally, 800 μL of cold ethanol were added and the mixture was chilled at −2 0 °C
for 1 hour in order to precipitate out the deglycosylated proteins. Following centrifugation,
released N-glycans were isolated in the supernatant fraction and dried in vacuo.
N-glycan enrichment with graphitized carbon SPE
Released N-glycans were purified by graphitized carbon (GC) solid-phase extraction (SPE).
GC cartridges were washed with 0.05% (v/v) trifluoroacetic acid in 80% acetonitrile/water
(v/v) followed by conditioning with water. The N-glycan fractions were reconstituted in
water and then washed with water at a flow rate of approximately 1 mL/min to remove salts
and buffer. Serum N-glycans were eluted stepwise with 10% acetonitrile/water (v/v), 20%
acetonitrile/water (v/v), and 0.05% (v/v) trifluoroacetic acid in 40% acetonitrile/water (v/v).
Samples were dried in vacuo prior to MS analysis.
Chromatographic separation of the serum N-glycome
N-glycan fractions were reconstituted in water and analyzed using an Agilent HPLC-Chip/
Time-of-Flight (Chip/TOF) MS system equipped with a microwell-plate autosampler
(maintained at 6 °C), capillary sample loading pump, nano pump, HPLC-Chip/MS interface,
and the Agilent 6210 TOF MS detector. The chip used consisted of a 9 × 0.075 mm i.d.
enrichment column and a 43 × 0.075 mm i.d. analytical column, both packed with 5 μm
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porous graphitized carbon (PGC) as the stationary phase, with an integrated nano-ESI spray
tip. For sample loading, the capillary pump delivered 0.1% formic acid in 3.0% acetonitrile/
water (v/v) isocratically at 4.0 μL/min. Injection volume was 2.0 μL for each sample. A
nano pump gradient was delivered at 0.3 μL/min using (A) 0.1% formic acid in 3.0%
acetonitrile/water (v/v) and (B) 0.1% formic acid in 90.0% acetonitrile/water (v/v). Samples
were eluted with 0% B, 0.00-2.50 min; 0 to 16% B, 2.50-20.00 min; 16 to 44% B,
20.00-30.00 min; 44 to 100% B, 30.00-35.00 min; and 100% B, 35.00-45.00 min. This was
followed by a quick gradient from 0 to 100% B in order to wash out any remaining
compounds, and finally re-equilibration at 0% B. The drying gas temperature was set at 325
°C with a flow rate of 4 L/min (2 L of filtered nitrogen gas and 2 L of filtered dry
compressed air). MS spectra were acquired in the positive ionization mode over a mass
range of m/z 400-2500 with an acquisition time of 1.5 seconds per spectrum. Mass
correction was enabled using reference masses of m/z 622.029, 922.010, 1221.991,
1521.971, 1821.952, and 2121.933 (ESI-TOF Calibrant Mix G1969-85000, Agilent
Technologies, Santa Clara, CA).
To minimize possible bias due to injection order and/or instrumental drift, samples were
injected in randomized order, using the same solvents, over the course of a single instrument




Serum N-glycans are a complex mixture with large structural diversity and dynamic range.
Incorporation of chromatographic separation into established mass spectral methods of
glycomic analysis allows us to distinguish between isomeric compounds of the same glycan
composition. The chip-based nano-LC/TOF-MS (Chip/TOF) system provides high
sensitivity, large instrumental dynamic range, minimal ion suppression, and low sample
consumption.29, 30 These attributes are uniquely suited to the analysis of serum N-glycans.
In order to ensure accurate, quantitative, and reproducible data that would span the serum N-
glycan dynamic range, method optimization was necessary. Optimal instrumental
parameters for high ionization efficiency and low in-source fragmentation had already been
established by our previous work with the Chip/TOF system.29, 30 To complement this
information, we examined chromatographic loading capacity and separation capabilities of
the chip-based nano-LC. Starting from an initial concentration (henceforth a “1x dilution”)
corresponding to 4 μL serum per 2 μL injection, samples were diluted to final concentrations
corresponding to 400 nL serum/injection (10x dilution); 40 nL serum/injection (100x
dilution); 15 nL serum/injection (300x dilution); and 9 nL serum/injection (500x dilution).
Sample dilutions were compared in order to optimize chromatographic separation and
detection of both low- and high-abundance serum N-glycans.
In order to evaluate glycan isomer separation capabilities, representative N-glycans were
selected for analysis based on characteristics such as structure, abundance, and interaction
strength with PGC. The high mass accuracy of the TOF MS detector enabled us to
confidently predict the expected m/z values of our selected N-glycans. The m/z values
associated with charge states 1 < z < 4 of each selected N-glycan composition were
computed, and extracted ion chromatograms (XICs) showing the abundance vs. time of the
selected N-glycans were plotted. Visual inspection of the XICs was sufficient to identify
saturated as well as low-abundance peaks (Figure 1).
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N-glycan abundances exhibited a large dynamic range spanning over five orders of
magnitude. As a result, high- and low-concentration analyses often returned complementary
information. At the extreme edges of the dynamic range, lower sample concentrations were
more suitable for effectively separating high-abundance glycans, whereas higher sample
concentrations were more suitable for detecting low-abundance glycans. Sample
concentration had to be optimized in order to maintain high chromatographic resolution and
baseline peak separation of isomers. Figure 1a shows the XICs of m/z 1112.40, i.e. the
doubly protonated [M+2H]+2 ion of the biantennary disialylated N-glycan (NB2) consisting
of Hex5-HexNAc4-NeuAc2 at dilutions of 1x, 10x, 100x, 300x, and 500x. In human serum,
NB2 is reported as the most abundant N-glycan.35 Accordingly, the chromatograms of the
1x and 10x dilutions show heavy saturation, with severe peak tailing, poor resolution, and
retention time shifts. In contrast, XICs of the low-abundance complex triantennary
disialylated N-glycan NT2 (Hex6-HexNAc5-NeuAc2) (Figure 1b) show that at the 1x
dilution, nano-LC/MS is able to resolve the glycans into several distinct peaks. However, as
the dilution factor increases, competive ionization leads to dramatic decreases in MS
sensitivity.
For the majority of compounds, however, a wide range of injection concentrations are
suitable for quantitative analysis. Figure 1c shows the XICs of m/z 942.33, i.e. the doubly
protonated ion of the high-mannose glycan Hex9-HexNAc2, at the same series of dilutions
(1x to 500x). Each dilution shows the same major and minor peaks with good resolution and
Gaussian peak distributions. In addition, retention times are highly reproducible, with
extremely slight deviation even at vastly different sample concentrations. One issue of note
is that, whereas the 10x to 500x dilutions follow the expected trend of decreasing XIC
abundances with increasing dilution factors, the abundances from the 1x dilution are in fact
lower than their 10x dilution equivalents. This phenomenon is also evident for the other
high-mannose glycan compositions, and is likely related to the previously noted column
saturation at the 1x dilution. As evidenced by their early retention times, high-mannose
glycans have a relatively weak interaction with porous graphitized carbon in comparison to
complex/hybrid sialylated compounds. Therefore, in cases of high column saturation, porous
graphitized carbon preferentially binds to complex/hybrid rather than high-mannose glycans.
Since each distinct glycan structure has a different interaction with porous graphitized
carbon, this explanation would also account for the dynamic isomer ratios observed
throughout the dilution series.
High- and low-concentration analyses returned complementary information; thus, the
samples were eventually analyzed at both the 1x and 300x dilutions in order to maximize
glycan coverage. This strategy effectively extended the experimental dynamic range of the
nano-LC/MS method and allowed accurate, quantitative analysis of both high- and low-
abundance aspects of the serum N-glycome.
Method reproducibility and sample variance
Serum N-glycan samples (n = 8) were analyzed in triplicate by nano-LC/MS. Peak
intensities and retention times were examined in order to establish the quantitative and
qualitative reproducibility of the method as well as the variance within the sample set.
Figure 2 shows 24 overlaid total ion chromatograms (TICs) of all serum samples from both
patient groups, injected in triplicate at a 300x dilution. Simple visual inspection highlights
the low sample-to-sample variance even across different patient groups and the need for
exceedingly precise measurements in order to differentiate between them.
Statistical tests were used to establish the quantitative precision, sensitivity, and
reproducibility of the method. Ion abundances corresponding to selected representative N-
glycans were subjected to two-factor analysis of variance (ANOVA), with patient group (P
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or G) as one factor and batch effect (first, second, or third replicate) as the other factor.
Using a 95% confidence level (p < 0.05), patient group was found to be a significant factor
for several N-glycans. Since patient groups corresponded to disease prognosis, these glycans
could be considered disease biomarkers within the scope of this sample set.
In contrast to patient group, ANOVA results showed batch effect to be an insignificant
factor (p > 0.05) in all tested glycans; i.e. each replicate was not significantly different from
the others. These results affirmed that instrumental drift was not a significant issue and the
collected data were indeed statistically independent of sample injection order. As a result,
batch effect was disregarded for subsequent statistical analyses, allowing the sole use of T-
tests.
The quantitative precision of the method was further tested by dividing the patient groups
into individual patients (n = 4) and subjecting the glycan abundance data to one-factor
ANOVA. In both patient groups, for all glycans tested, the individual patient was found to
be a significant factor (p < 0.05); i.e. the method was precise enough to differentiate even
among individual patients from the same patient group.
Qualitative aspects of the method reproducibility, such as retention time, were analyzed by
computer algorithm. Every single X-Y coordinate (n = 600) of the TIC function was
compared to its corresponding X-Y coordinate in every other TIC function (n = 24), and the
distance between each was recorded. From this data, average differences in the X axis
(retention time) were calculated. In general, chromatograms of 300x diluted samples ion
exhibited less run-to-run variance than chromatograms of undiluted (1x) samples. For the
300x dilution chromatograms, average retention time difference was only 5.0 seconds ± 2.7
seconds, while for the undiluted 1x chromatograms, average retention time difference
increased to 7.9 seconds ± 3.7 seconds. The loss of retention time reproducibility from the
300x to 1x runs emphasize the importance of column loading to precise glycan analysis.
Aside from column loading, much of the observed variation stemmed from the extreme
sensitivity of highly sialylated, acidic glycans such as NB2 to gradient changes. Indeed,
when NB2 was removed from the comparison, retention time reproducibility for the 300x
dilution increased dramatically to 3.7 seconds ± 1.5 seconds. Work is ongoing to optimize
the elution gradient and stabilize retention times for this particular glycan class.
Detection and identification of N-glycans
In order to obtain N-glycan profiles of each serum sample, computerized algorithms first
extracted a generalized list of compound peaks in the sample and then identified the N-
glycan compositions by accurate mass.
Raw LC/MS data was filtered with a signal-to-noise ratio of 5.0 and analyzed using the
Molecular Feature Extractor algorithm included in the MassHunter Qualitative Analysis
software (Version B.03.01, Agilent Technologies). Taking into account expected charge
carriers, potential neutral mass losses, and a predicted isotopic distribution, the total ion
chromatogram (TIC) was divided into a number of extracted compound chromatograms
(ECCs) (Figure 3). Each ECC represents the summed chromatograms of all ion species
associated with a single compound (e.g. the singly protonated, doubly protonated, singly
dehydrated, etc. ions). Thus, each individual ECC peak could be taken to represent the total
ion count associated with a single distinct compound.
The deconvoluted mass, retention time, abundance (in summed ion counts), and observed
charge states associated with each extracted compound were exported for further analysis.
N-glycans were identified by accurate mass using a set of in-house software tools. A mass
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error tolerance of 20 ppm was used. As the sample set originated from human serum, only
N-glycan compositions containing hexose (Hex), N-acetylhexosamine (HexNAc), fucose
(Fuc), and N-acetylneuraminic acid (NeuAc) were considered. To aid these types of
analyses, our laboratory has developed theoretical N-glycan mass libraries that cover all
possible complex, hybrid, and high-mannose glycan compositions based on known
biological synthesis pathways and glycosylation patterns36. Using these search criteria, N-
glycan compositions were identified and correlated with abundances and retention times.
On average, our nano-LC method was able to resolve and identify over 300 N-linked glycan
compound peaks with over 100 distinct N-linked glycan compositions spanning five orders
of magnitude in abundance (Figure 3). Each of the identified compositions included two or
more peaks corresponding to structural and/or linkage isomers. The high reproducibility of
the nano-LC means that a specific glycan structure will have the same retention time in
different samples across multiple chromatographic runs. While each peak/retention time has
not yet undergone full structural elucidation, libraries that match chip-based PGC nano-LC
retention times to specific glycan structures are currently under development in our
laboratory.
Glycan separation by porous graphitized carbon (PGC)
PGC has been used as a stationary phase to separate glycans based on size, polarity, and
three-dimensional structure.37, 38 Traditionally, LC separation of native glycans has been
done using PGC as well as amine/amide and anion-exchange stationary phases.39, 40 PGC
columns offer distinct advantages over these other stationary phases such as low column-to-
column variability, stability over a large pH range, and the ability to separate neutral and
acidic glycans within a single run.41, 42 In particular, the PGC nano-LC system presented
herein has been successfully demonstrated in the past to separate glycan isomers.29, 30
Nano-LC separation of serum N-glycans by PGC exhibited a number of consistent trends
(Figure 3). In most cases, smaller, simpler glycans eluted earlier, while larger, more
complex glycans eluted later. In particular, sialylation increased retention time additively,
with higher degrees of sialylation associated with correspondingly later retention times.
Core fucosylation, i.e. addition of a fucose monosaccharide to the N-glycan core, was also
observed to increase retention times relative to equivalent non-fucosylated compounds.
Addition of a Hex or HexNAc increased retention times in biantennary N-glycans; however,
the effect on the retention times of triantennary N-glycans was less predictable. Notably, the
triantennary high-mannose glycans eluted in order from largest (Hex9-HexNAc2) to smallest
(Hex5-HexNAc2).
The demonstrated ability of PGC to separate isomeric glycans is related to differences in
sugar-sugar linkages which lead to changes in the three-dimensional structure of
compositionally identical glycans.37, 38 A triantennary N-glycan has a significantly different
three-dimensional structure from a biantennary glycan of similar size and composition.43 As
a result, it exhibits modified interactions with both the porous graphitized carbon stationary
phase as well as the acetonitrile/water mobile phase. These account for the modified elution
orders seen with triantennary glycans.
Glycan compositional profiling for biomarker discovery
In order to simplify the analysis and obtain a generalized view of the cancer serum glycome,
compositional N-glycan profiling was applied as a data-reduction method.
An overall perspective of the N-glycan content of serum from prostate cancer patients was
gained by grouping together N-glycans of similar composition or structure and analyzing
them as a correlated set. Individual glycan compounds were sorted into several N-glycan
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classes— 1) high-mannose glycans; 2) undecorated complex/hybrid glycans; 3) fucosylated
(but nonsialylated) complex/hybrid glycans; 4) sialylated (but non-fucosylated) complex/
hybrid glycans; and 5) fucosylated and sialylated complex/hybrid glycans. Abundances were
calculated relative to the total ion abundance of all N-glycans in a particular nano-LC run;
i.e. relative abundance. Sialylated, non-fucosylated complex/hybrid glycans were found to
be the most abundant N-glycan class in both patient groups, at 52.8% relative abundance in
patients with poor prognoses (P group) and 47.9% relative abundance in patients with good
prognoses (G group). High abundances were also found of fucosylated and sialylated
complex/hybrid glycans (24.8% in the P group; 25.5% in the G group) as well as
fucosylated, non-sialylated complex/hybrid glycans (18.5% in the P group; 22.6% in the G
group). In contrast, low abundances were found of undecorated complex/hybrid glycans
(2.05% in the P group; 2.17% in the G group) and high-mannose glycans (1.87% in the P
group; 1.78% in the G group). Figure 4 summarizes the different relative abundances of
each N-glycan class found in the P and G patient groups. In order to determine whether
differences between the P and G groups were significant, standard T-tests were performed.44
Fucosylated, non-sialylated complex/hybrid glycans were significantly more abundant in the
G group than in the P group (p = 0.0495). In addition, sialylated, nonfucosylated complex/
hybrid glycans were significantly more abundant in the P group than in the G group (p =
0.00758). These results provide a macro perspective of the glycosylation changes associated
with prostate cancer and may help highlight glycan synthesis pathways that are affected by
disease. However, when searching for clinically significant biomarkers, a more detailed and
compound-specific approach would be desired, e.g. compositional or isomer-specific
profiling.
A more detailed analysis of the serum N-glycan profile was obtained by separately
considering each individual N-glycan composition. Table 1 summarizes the relative
abundances of the top twenty most abundant N-glycans found in serum from prostate cancer
patients. N-glycans from patients with poor prognoses (P group) were observed at different
relative abundances compared to sera from patients with good prognoses (G group). T-tests
were again used to determine the significance of these differences. Relative as well as
absolute abundances were compared using data from both the 1x and 300x dilutions.
Various levels of significance were tested, with 48 N-glycan compositions found at p <
0.100, 36 N-glycan compositions found at p < 0.050, 18 N-glycan compositions found at p <
0.010, and 6 N-glycan compositions found at p < 0.001. N-glycan compositions with
statistically significant differences between the P and G groups included fucosylated,
sialylated, and high-mannose type glycans. These results are summarized in Table 2.
Glycan chromatographic profiling for biomarker discovery
The main advantage of PGC nano-LC/MS analysis is the ability to distinguish between
isomeric glycans. Identifying specific isomers which exhibit significant differences in
abundance provides a window into the up- and down-regulation of glycosyltransferase
activity under different biological conditions. While the nano-LC methodology described
herein is easily capable of separating out and resolving glycan isomers, the associated data
analysis is more time- and labor-intensive due to the computational complexities associated
with peak recognition algorithms and retention time alignment. The present analysis focused
on representative fucosylated, sialylated, and high-mannose type glycans as well as
statistically interesting glycans (p < 0.01) identified during compositional profiling. Nano-
LC was able to separate up to six different isomers for each composition.
Computerized algorithms identified the beginning and end of each chromatographic peak
and calculated absolute abundances of each isomer in terms of ion counts. From this data,
relative abundances of each isomer were calculated by dividing the ion abundance of a
particular isomer over the total ion abundance of all isomers with that composition. High
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retention time reproducibility allowed peaks from different samples and runs to be aligned
and compared. Both absolute and relative abundances were tested for significant differences.
Overall, 38 isomers from 19 N-glycan compositions showed significant differences between
the P and G groups. Differences in isomer absolute abundances were found in 33 isomers
from 17 N-glycan compositions, while differences in isomer relative abundances were found
in 15 isomers from 9 N-glycan compositions. Several glycan isomers showed differences in
both absolute and relative abundances. Results are summarized in Supplemental Table 1.
Figure 5a shows the overlaid raw extracted compound chromatograms (ECCs) for the
complex triantennary N-glycan composition Hex3-HexNAc5. Two isomers are observed in
the sera of both patient groups. However, the absolute abundances of both isomers are
higher in the P group than the G group. Figure 5b represents the same data in bar graph
form. T-tests of absolute abundances show that the isomer eluting at 15.5 minutes is indeed
significantly more abundant in the P group, with a p-value of 6.50×10−5, while the isomer
eluting at 16.6 minutes is also significantly more abundant in the P group, with a p-value of
5.25×10−5. However, comparisons of relative abundances show that both isomers appeared
at more or less the same ratios in both groups, exhibiting no significant difference between
the P and G groups.
Figure 6 shows the raw ECCs and representative bar graphs for the high-mannose glycan
composition Hex9-HexNAc2. Three isomers are observed in the sera of both patient groups.
T-tests of absolute abundances show that the isomers at 17.9 minutes (p = 0.0351), 19.2
minutes (p = 0.0392), and 19.9 minutes (p = 0.00180) are significantly more abundant in the
P group than in the G group. T-tests of relative abundances show that the isomers at 17.9
minutes and 19.9 minutes appeared at more or less the same ratios in both groups, exhibiting
no significant difference between the P and G groups, whereas the isomer at 19.2 minutes
appeared at a significantly lower ratio in the P group than in the G group, with a p-value of
0.0281.
It should be noted that, in some cases, the glycan isomers separated by nano-LC may include
alpha and beta anomers. However, in our experience, anomeric separation does not always
occur, or may be insignificant when it does occur. This is supported by the existence of
multiple glycan masses for which an odd number of isomers have been detected. Given the
exceptionally high retention time reproducibility demonstrated by this nano-LC method,
detection and identification of any potential anomer peaks may easily be addressed in the
future with the use of retention time libraries currently under development by our lab.
CONCLUSION
We have demonstrated for the first time comprehensive, isomer-specific chromatographic
profiling of serum N-glycans for the purposes of biomarker discovery. Chip-based porous
graphitized carbon nano-LC/MS was applied to interrogate native serum N-glycans. Nano-
LC run conditions were optimized, resulting in highly reproducible glycan retention times
and abundances across all samples and sample replicates. Over 300 N-linked glycan
compound peaks with over 100 distinct N-linked glycan compositions were identified.
General glycan elution trends revealed complex interactions with porous graphitized carbon
based not only on saccharide composition and associated functional groups but also the
three-dimensional geometry of the glycan branches and linkages.
The developed method was applied to serum samples from prostate cancer patients with
good (n = 4) and bad (n = 4) prognoses. Chromatographic profiling was performed with
respect to N-glycan composition as well as individual isomer-specific structure. Overall
compositional profiling was applied first as a data-reduction method. Results compared
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favorably with previously reported compositional profiling methods,14-20 with high
sensitivity and a wide dynamic range. Relative abundances of fucosrylated, sialylated, and
high-mannose type glycans were determined. Isomer-specific analysis revealed that PGC
nano-LC was able to separate up to six different isomers for each N-glycan composition.
Highly reproducible abundances allowed compositional as well as isomer-specific statistical
analysis. A number of significant differences were found between N-glycan abundances in
patients with poor versus good prognoses.
Glycan chromatographic profiling was shown to be a powerful new technique for
characterization of the serum N-glycome. In addition to highly sensitive compositional
profiling, isomer-specific glycan quantitation will add a new dimension to existing glycomic
analyses. Work is ongoing to further increase the speed, sensitivity, and dynamic range of
this method. The combination of chromatographic profiling with structure-specific retention
time and tandem MS libraries currently being developed by our lab will allow rapid and
accurate identification of N-glycan structure. From a biomarker discovery perspective,
application of high-throughput glycan chromatographic profiling to larger sample sets will
greatly improve the statistical power of these comparisons and enable the identification of
many more potential biomarkers.
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MALDI matrix-assisted laser desorption/ionization
ESI electrospray ionization
MS mass spectrometry
HPLC High performance liquid chromatography
TOF time-of-flight
PGC porous graphitized carbon
SPE solid phase extraction
TIC total ion chromatogram
XIC extracted ion chromatogram
ECC extracted compound chromatogram
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a) XICs of m/z 1112.40, i.e. the doubly protonated ion of the high-abundance complex
biantennary disialylated glycan (NB2) at dilutions of 1x, 10x, 100x, 300x, and 500x (top to
bottom). b) XICs of the low-abundance complex triantennary disialylated glycan (NT2) at
dilutions of 1x, 10x, 100x, 300x, and 500x. c) XICs of m/z 942.33, i.e. the doubly protonated
ion of the high-mannose glycan composition Hex9-HexNAc2, at dilutions of 1x, 10x, 100x,
300x, and 500x.
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Overlaid total ion chromatograms (TICs) (n=24) of all serum samples from both patient
groups, injected in triplicate at a 300x dilution. Average retention time difference between
chromatograms was only 5.0 seconds ± 2.7 seconds.
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a) Extracted compound chromatograms (ECCs) of glycans found in a representative serum
sample. b) Magnified view of a short segment of the glycan elution profile, showing the high
sensitivity and resolution achieved by nano-LC separation. Colors denote different glycan
classes.
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Relative abundances of high-mannose glycans, undecorated complex/hybrid (C/H) glycans,
fucosylated (but non-sialylated) C/H glycans, sialylated (but non-fucosylated) C/H glycans,
and finally, fucosylated and sialylated C/H glycans found in the P and G patient groups.
Asterisks denote statistically significant differences (p < 0.05) between patient groups.
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a) Overlaid chromatograms of the isomers of complex triantennary glycan composition
Hex3-HexNAc5. Overlaps are represented by varying degrees of translucency. b) Bar graph
representation of average abundances and standard error for the isomers of Hex3- HexNAc5.
Asterisks denote statistically significant differences between patient groups.
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a) Overlaid chromatograms of the isomers of high-mannose glycan composition
Hex9-HexNAc2. Overlaps are represented by varying degrees of translucency. b) Bar graph
representation of average abundances and standard error for the isomers of Hex9-HexNAc2.
Asterisks denote statistically significant differences between patient groups.
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